Vertex Pharmaceuticals (VRTX) Tax Provisions (2011 - 2026)
Vertex Pharmaceuticals' quarterly Tax Provisions came in at $221.5 million in Q1 2026, up 163.38% year-on-year from $84.1 million in Q1 2025, and up 58.33% quarter-over-quarter from $139.9 million in Q4 2025.
Vertex Pharmaceuticals has reported Tax Provisions for 16 years, with the latest figure at $221.5 million in Q1 2026.
- For the quarter ending Q1 2026, Tax Provisions rose 163.38% year-over-year to $221.5 million; the trailing twelve-month figure through Mar 2026 stood at $827.4 million (up 20.14% YoY), and the FY2025 full-year result was $690.0 million, down 12.0% from the prior year.
- Tax Provisions for Q1 2026 stood at $221.5 million, up from $139.9 million in the prior quarter.
- The five-year high for Tax Provisions was $257.9 million in Q4 2022, with the low at $84.1 million in Q1 2025.
- Average Tax Provisions over 5 years is $198.0 million, with a median of $202.4 million recorded in 2024.
- Year-over-year, Tax Provisions jumped 292.36% in 2022 and sank 53.15% in 2025.
- Tracing VRTX's Tax Provisions over 5 years: stood at $257.9 million in 2022, then slumped by 30.67% to $178.8 million in 2023, then increased by 25.0% to $223.5 million in 2024, then slumped by 37.4% to $139.9 million in 2025, then jumped by 58.33% to $221.5 million in 2026.
- The last three Tax Provisions figures came in at $221.5 million (Q1 2026), $139.9 million (Q4 2025), and $215.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -11.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -859,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 221.50 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 216,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 104.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 15.66 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 221.50 Mn |
| Dec 31, 2025 | 139.90 Mn |
| Sep 30, 2025 | 215.90 Mn |
| Jun 30, 2025 | 250.10 Mn |
| Mar 31, 2025 | 84.10 Mn |
| Dec 31, 2024 | 223.50 Mn |
| Sep 30, 2024 | 178.70 Mn |
| Jun 30, 2024 | 202.40 Mn |
| Mar 31, 2024 | 179.50 Mn |
| Dec 31, 2023 | 178.80 Mn |
| Sep 30, 2023 | 143.90 Mn |
| Jun 30, 2023 | 245.80 Mn |
| Mar 31, 2023 | 191.70 Mn |
| Dec 31, 2022 | 257.90 Mn |
| Sep 30, 2022 | 245.90 Mn |
| Jun 30, 2022 | 213.90 Mn |
| Mar 31, 2022 | 192.70 Mn |
| Dec 31, 2021 | 100.80 Mn |
| Sep 30, 2021 | 230.90 Mn |
| Jun 30, 2021 | -111.20 Mn |
| Mar 31, 2021 | 167.80 Mn |
| Dec 31, 2020 | 284.43 Mn |
| Sep 30, 2020 | 78.44 Mn |
| Jun 30, 2020 | -12.50 Mn |
| Mar 31, 2020 | 54.78 Mn |
| Dec 31, 2019 | 93.72 Mn |
| Sep 30, 2019 | 13.15 Mn |
| Jun 30, 2019 | 59.71 Mn |
| Mar 31, 2019 | 51.53 Mn |
| Dec 31, 2018 | -1.49 Bn |
| Sep 30, 2018 | 8.06 Mn |
| Jun 30, 2018 | 10.34 Mn |
| Mar 31, 2018 | -12.66 Mn |
| Dec 31, 2017 | 10.26 Mn |
| Sep 30, 2017 | -126.20 Mn |
| Jun 30, 2017 | 4.34 Mn |
| Mar 31, 2017 | 3.99 Mn |
| Dec 31, 2016 | -7.45 Mn |
| Sep 30, 2016 | 503,000.00 |
| Jun 30, 2016 | 18.13 Mn |
| Mar 31, 2016 | 5.49 Mn |
| Dec 31, 2015 | -1.38 Mn |
| Sep 30, 2015 | 1.33 Mn |
| Jun 30, 2015 | 30.13 Mn |
| Mar 31, 2015 | 299,000.00 |
| Dec 31, 2014 | 2.04 Mn |
| Sep 30, 2014 | 3.42 Mn |
| Jun 30, 2014 | 693,000.00 |
| Mar 31, 2014 | 803,000.00 |
| Dec 31, 2013 | 1.35 Mn |
| Sep 30, 2013 | 2.56 Mn |
| Jun 30, 2013 | 558,000.00 |
| Mar 31, 2013 | -126.89 Mn |
| Dec 31, 2012 | -2.70 Mn |
| Sep 30, 2012 | 21.36 Mn |
| Jun 30, 2012 | 20.06 Mn |
| Mar 31, 2012 | 32,000.00 |
| Dec 31, 2011 | 22.66 Mn |
| Sep 30, 2011 | -27.84 Mn |